RB1 and retinoblastoma: Finally, these results support consideration of evaluating patients with retinoblastoma undergoing cfDNA testing with persistent RB1 variants in cfDNA but no clinical evidence of disease for RB1 mosaicism to reduce the chance of a false-positive interpretation or overtreatment.